Browse NCBP2

Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm
Domain PF00076 RNA recognition motif. (a.k.a. RRM
Function

Component of the cap-binding complex (CBC), which binds co-transcriptionally to the 5' cap of pre-mRNAs and is involved in various processes such as pre-mRNA splicing, translation regulation, nonsense-mediated mRNA decay, RNA-mediated gene silencing (RNAi) by microRNAs (miRNAs) and mRNA export. The CBC complex is involved in mRNA export from the nucleus via its interaction with ALYREF/THOC4/ALY, leading to the recruitment of the mRNA export machinery to the 5' end of mRNA and to mRNA export in a 5' to 3' direction through the nuclear pore. The CBC complex is also involved in mediating U snRNA and intronless mRNAs export from the nucleus. The CBC complex is essential for a pioneer round of mRNA translation, before steady state translation when the CBC complex is replaced by cytoplasmic cap-binding protein eIF4E. The pioneer round of mRNA translation mediated by the CBC complex plays a central role in nonsense-mediated mRNA decay (NMD), NMD only taking place in mRNAs bound to the CBC complex, but not on eIF4E-bound mRNAs. The CBC complex enhances NMD in mRNAs containing at least one exon-junction complex (EJC) via its interaction with UPF1, promoting the interaction between UPF1 and UPF2. The CBC complex is also involved in 'failsafe' NMD, which is independent of the EJC complex, while it does not participate in Staufen-mediated mRNA decay (SMD). During cell proliferation, the CBC complex is also involved in microRNAs (miRNAs) biogenesis via its interaction with SRRT/ARS2, thereby being required for miRNA-mediated RNA interference. The CBC complex also acts as a negative regulator of PARN, thereby acting as an inhibitor of mRNA deadenylation. In the CBC complex, NCBP2/CBP20 recognizes and binds capped RNAs (m7GpppG-capped RNA) but requires NCBP1/CBP80 to stabilize the movement of its N-terminal loop and lock the CBC into a high affinity cap-binding state with the cap structure. The conventional cap-binding complex with NCBP2 binds both small nuclear RNA (snRNA) and messenger (mRNA) and is involved in their export from the nucleus (PubMed:26382858).

> Gene Ontology
 
Biological Process GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000398 mRNA splicing, via spliceosome
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0006353 DNA-templated transcription, termination
GO:0006354 DNA-templated transcription, elongation
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006369 termination of RNA polymerase II transcription
GO:0006370 7-methylguanosine mRNA capping
GO:0006379 mRNA cleavage
GO:0006397 mRNA processing
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006403 RNA localization
GO:0006405 RNA export from nucleus
GO:0006406 mRNA export from nucleus
GO:0006408 snRNA export from nucleus
GO:0006413 translational initiation
GO:0006417 regulation of translation
GO:0006446 regulation of translational initiation
GO:0006913 nucleocytoplasmic transport
GO:0008334 histone mRNA metabolic process
GO:0008380 RNA splicing
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0009301 snRNA transcription
GO:0009452 7-methylguanosine RNA capping
GO:0010608 posttranscriptional regulation of gene expression
GO:0015931 nucleobase-containing compound transport
GO:0016073 snRNA metabolic process
GO:0016458 gene silencing
GO:0019439 aromatic compound catabolic process
GO:0031047 gene silencing by RNA
GO:0031123 RNA 3'-end processing
GO:0031124 mRNA 3'-end processing
GO:0031440 regulation of mRNA 3'-end processing
GO:0031442 positive regulation of mRNA 3'-end processing
GO:0032239 regulation of nucleobase-containing compound transport
GO:0032241 positive regulation of nucleobase-containing compound transport
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0034248 regulation of cellular amide metabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0036260 RNA capping
GO:0042795 snRNA transcription from RNA polymerase II promoter
GO:0044270 cellular nitrogen compound catabolic process
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045292 mRNA cis splicing, via spliceosome
GO:0046700 heterocycle catabolic process
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0046831 regulation of RNA export from nucleus
GO:0046833 positive regulation of RNA export from nucleus
GO:0050657 nucleic acid transport
GO:0050658 RNA transport
GO:0050684 regulation of mRNA processing
GO:0050685 positive regulation of mRNA processing
GO:0051028 mRNA transport
GO:0051030 snRNA transport
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051236 establishment of RNA localization
GO:0071166 ribonucleoprotein complex localization
GO:0071426 ribonucleoprotein complex export from nucleus
GO:0071427 mRNA-containing ribonucleoprotein complex export from nucleus
GO:0071774 response to fibroblast growth factor
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0090501 RNA phosphodiester bond hydrolysis
GO:0098781 ncRNA transcription
GO:0098787 mRNA cleavage involved in mRNA processing
GO:0098789 pre-mRNA cleavage required for polyadenylation
GO:1901361 organic cyclic compound catabolic process
GO:1903311 regulation of mRNA metabolic process
GO:1903313 positive regulation of mRNA metabolic process
Molecular Function GO:0000339 RNA cap binding
GO:0000340 RNA 7-methylguanosine cap binding
GO:0003729 mRNA binding
GO:0017069 snRNA binding
Cellular Component GO:0005845 mRNA cap binding complex
GO:0005846 nuclear cap binding complex
GO:0034518 RNA cap binding complex
> KEGG and Reactome Pathway
 
KEGG hsa03013 RNA transport
hsa03015 mRNA surveillance pathway
hsa03040 Spliceosome
Reactome R-HSA-167242: Abortive elongation of HIV-1 transcript in the absence of Tat
R-HSA-109688: Cleavage of Growing Transcript in the Termination Region
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-6803529: FGFR2 alternative splicing
R-HSA-1839126: FGFR2 mutant receptor activation
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-113418: Formation of the Early Elongation Complex
R-HSA-167158: Formation of the HIV-1 Early Elongation Complex
R-HSA-74160: Gene Expression
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-194441: Metabolism of non-coding RNA
R-HSA-975957: Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
R-HSA-975956: Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
R-HSA-927802: Nonsense-Mediated Decay (NMD)
R-HSA-112296: Post-Elongation Processing of Intron-Containing pre-mRNA
R-HSA-112297: Post-Elongation Processing of Intronless pre-mRNA
R-HSA-76044: Post-Elongation Processing of the Transcript
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-75067: Processing of Capped Intronless Pre-mRNA
R-HSA-77595: Processing of Intronless Pre-mRNAs
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-73856: RNA Polymerase II Transcription Termination
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
R-HSA-77588: SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
R-HSA-111367: SLBP independent Processing of Histone Pre-mRNAs
R-HSA-162582: Signal Transduction
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654738: Signaling by FGFR2
R-HSA-8851708: Signaling by FGFR2 IIIa TM
R-HSA-5655253: Signaling by FGFR2 in disease
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-72202: Transport of Mature Transcript to Cytoplasm
R-HSA-159231: Transport of Mature mRNA Derived from an Intronless Transcript
R-HSA-159236: Transport of Mature mRNA derived from an Intron-Containing Transcript
R-HSA-159234: Transport of Mature mRNAs Derived from Intronless Transcripts
R-HSA-159230: Transport of the SLBP Dependant Mature mRNA
R-HSA-159227: Transport of the SLBP independent Mature mRNA
R-HSA-72187: mRNA 3'-end processing
R-HSA-72086: mRNA Capping
R-HSA-72172: mRNA Splicing
R-HSA-72163: mRNA Splicing - Major Pathway
R-HSA-72165: mRNA Splicing - Minor Pathway
R-HSA-191859: snRNP Assembly
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NCBP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NCBP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.62 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NCBP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0640.748
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4360.868
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.210.914
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2680.26
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3040.857
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2250.918
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0240.956
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0230.99
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0050.998
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3840.819
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2190.929
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0550.368
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NCBP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NCBP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NCBP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NCBP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NCBP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NCBP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNCBP2
Namenuclear cap binding protein subunit 2, 20kDa
Aliases CBP20; Cbc2; nuclear cap binding protein subunit 2, 20kD; PIG55; 20 kDa nuclear cap-binding protein; NCBP 20 ......
Chromosomal Location3q29
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NCBP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.